Alan Held Erased His Cancer With Theranostics
Alan Held underwent a groundbreaking theranostics treatment for prostate cancer in Germany. This innovative approach, led by Dr. Frankis Almaguel at Loma Linda University Medical Center, eradicated 80% of Held’s cancer cells after just one session. With thousands benefiting from theranostics in Germany, the FDA has now approved Theranostics for use in the U.S., signaling a transformative shift in prostate cancer care. The before and after shows Mr. Held’s results from treatment with Theranostics.
We are the experts in using Theranostics to fight Cancer more intelligently.
Meet our Medical Director, Dr. Frankis Almaguel, MD, PhD, an unparalleled expert in Theranostics with a unique blend of extensive research and hands-on patient care knowledge.
Nuclear Oncologist at Loma Linda University Cancer Center
Leads the Molecular Imaging & Therapeutics Program at Loma Linda
Specializes in Prostate Cancer & Nuclear Oncology
Has been the lead researcher for numerous Clinical Trials for Theranostics in Prostate Cancer, Breast Cancer and 26 other cancer types
Has treated more patients with Theranostics than any other provider in the world
What is Theranostics? Privado's Chief Medical Officer, Dr. Frankis Almaguel
Dr. Frankis Almaguel describes the cutting edge new treatment for Prostate Cancer, Theranostics.
Theranostics saved my life.
MEET ALAN
Alan Held underwent a groundbreaking theranostics treatment for prostate cancer in Germany. This innovative approach, led by Dr. Frankis Almaguel at Loma Linda University Medical Center, eradicated 80% of Held's cancer cells after just one session. With thousands benefiting from theranostics in Germany, the FDA has now approved Theranostics for use in the U.S., signaling a transformative shift in prostate cancer care.
Oncologists
Oncologists are crucial partners with their patients – they manage cancer diagnosis, treatment, and care. In turn, Privado Health is here to partner with oncologists to provide their patients with another possible choice for prostate cancer treatment: Theranostics. Our goal is to prolong the lifespan of cancer patients while improving the patient’s quality of life during and after treatment. We understand prostate cancer is a complex disease, and we are committed to providing oncologists with another effective diagnostic and therapeutic tool, one they can add to their variety of treatment options.
de precise nuclear radiation treatment to the cancer cells, while minimizing damage to healthy tissue.
Urologists
Urologists are often the initial specialists who work with patients to navigate the many stages of prostate cancer. At Privado Health, we help urologists learn about Theranostics as an alternative treatment for prostate cancer patients. We are available to partner with urologists and their practices for a mutually beneficial relationship where optimal patient care comes first. The option to perform Theranostics treatment at urology clinics will provide expanded patient choice and improved outcomes for many qualified candidates.
Oncology Centers
Privado Health is helping to increase cancer treatment options by bringing Theranostics to an ever-expanding group of oncology centers. Bringing Theranostics to your oncology center can help you to maximize your patients’ care and outcomes. Our company deftly manages logistics to ensure that everyone who needs it has access to this groundbreaking treatment.
Clinical Trials
Privado Health is working with a number of leading nuclear medicine doctors who specialize in prostate cancer diagnosis and treatment. We will soon be helping to set up and conduct clinical trials to evaluate this new and innovative option that addresses an increasing range of cancers. We are passionate about bringing Theranostics to as many people who could benefit from it as possible. Clinical trials are a necessary step in proving the efficacy and relative safety of breakthrough solutions to challenging diseases like prostate cancer.
“It just kept getting better,” Held says. “It just kept erasing the cancer.”
